This randomized controlled clinical trial compares ultrasound-guided local ozone injection, extracorporeal shock wave therapy, and conventional conservative treatment in patients with chronic Achilles tendinopathy. The study focuses on changes in pain, functional outcomes, and overall clinical improvement during the follow-up period.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Patients aged 18 to 65 years.
Patients with a diagnosis of Achilles tendinopathy confirmed by ultrasonography or magnetic resonance imaging (MRI).
Patients with persistent symptoms despite completion of conservative treatment.
Volunteers who agree to participate in the study.
Exclusion Criteria:
Patients with symptoms lasting less than 12 weeks.
Presence of contraindications to extracorporeal shock wave therapy (ESWT), including pregnancy; history of thrombosis; use of anticoagulant medications; coagulation disorders such as hemophilia; systemic conditions; or localized conditions at the treatment site such as active infection or malignant tumors.
Presence of contraindications to local ozone injection, including pregnancy; glucose-6-phosphate dehydrogenase (G6PD) deficiency; favism; uncontrolled hyperthyroidism; thrombocytopenia; severe cardiovascular conditions; and use of angiotensin-converting enzyme (ACE) inhibitors.
History of neurological disease, muscle disease, or peripheral vascular disease.
Presence of congenital or acquired deformities of the knee and/or ankle.
Receipt of physical therapy modalities applied to the Achilles tendon within the last 6 weeks.
Receipt of any therapeutic injection to the Achilles tendon within the last 12 weeks.
History of direct trauma to the symptomatic Achilles tendon or Achilles tendon rupture.
History of surgical treatment involving the Achilles tendon or ankle for any reason.
History of foot or ank…
What they're measuring
1
Pain intensity (Visual Analog Scale, VAS)
Timeframe: Baseline, post-treatment, and 12 weeks after treatment
2
Pain intensity assessed by Visual Analog Scale (VAS)
Timeframe: Baseline, post-treatment, and 12-week follow-up